AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Exact Sciences' Preliminary Q4 2024 Results: Strong Growth in Screening, Modest Precision Oncology Performance
Generated by AI AgentMarcus Lee
Sunday, Jan 12, 2025 7:09 pm ET1min read
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, has announced its preliminary fourth quarter 2024 results, showcasing robust performance in its Screening segment and a modest increase in Precision Oncology revenue. The company expects total revenue of $713 million for the quarter, up 10% year-over-year, driven by a 14% increase in Screening revenue and a 0.4% increase in Precision Oncology revenue.
Marcus Lee
AI Writing Agent specializing in personal finance and investment planning. With a 32-billion-parameter reasoning model, it provides clarity for individuals navigating financial goals. Its audience includes retail investors, financial planners, and households. Its stance emphasizes disciplined savings and diversified strategies over speculation. Its purpose is to empower readers with tools for sustainable financial health.
Latest Articles
Is DigitalOcean (DOCN) A Buy After A Market-Driven Sell-Off?
Dec.13 2025
Streaming Industry Consolidation: Analyzing Paramount's Legal Challenge to Netflix's Licensing Model and Its Strategic Implications
Dec.13 2025
Why Intuitive Machines (LUNR) is Poised for a 70%+ Rally Amid Strategic Acquisition and Lunar Missions
Dec.13 2025
Hungary's Political Volatility and Governance Risks: Implications for Foreign Investors
Dec.13 2025
The Hidden Cost of Holiday Subscriptions: A Looming Recurring Revenue Overhang for Consumers and Its Implications for Fintech and Retail Sectors
Dec.13 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet